Addex Therapeutics (ADXN) Stock Price, News & Analysis

Company Overview

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Key Stats

• Today's Range: $8.01 to $8.01
• 50-Day Range: $7.01 to $9.00
• 52-Week Range: $6.67 to $27.90
• Volume: 1,017 shs
• Average Volume: 93,713 shs
• Market Capitalization: $8.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Buy

Addex Therapeutics Stock Analysis - MarketRank™

Addex Therapeutics scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Addex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Addex Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Addex Therapeutics is -22.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Addex Therapeutics is -22.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Addex Therapeutics has a P/B Ratio of 6.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.13% of the float of Addex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Addex Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Addex Therapeutics has recently decreased by 15.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Addex Therapeutics does not currently pay a dividend.

Dividend Growth

Addex Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.13% of the float of Addex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Addex Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Addex Therapeutics has recently decreased by 15.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Addex Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Addex Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Addex Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Addex Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.14% of the stock of Addex Therapeutics is held by institutions.

ADXN Stock Analysis - Frequently Asked Questions

How have ADXN shares performed this year?

Addex Therapeutics' stock was trading at $7.00 at the beginning of 2025. Since then, ADXN stock has increased by 10.2% and is now trading at $7.7150.
View the best growth stocks for 2025 here.

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) posted its quarterly earnings results on Friday, November, 22nd. The company reported ($2.77) EPS for the quarter, missing the consensus estimate of ($1.40) by $1.37. Addex Therapeutics had a net margin of 850.30% and a negative trailing twelve-month return on equity of 112.43%.

When did Addex Therapeutics' stock split?

Shares of Addex Therapeutics reverse split before market open on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Addex Therapeutics' major shareholders?

Top institutional shareholders of Addex Therapeutics include Citadel Advisors LLC (1.14%).

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Addex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Arista Networks (ANET), Adobe (ADBE), NVIDIA (NVDA), Broadcom (AVGO), General Electric (GE), Vista Energy (VIST) and Arch Capital Group (ACGL).

Company Calendar

• Last Earnings: 11/22/2024
• Today: 3/28/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADXN
• CIK: 1574232
• Web: www.addextherapeutics.com
• Phone: 011-41-22-884-1555
• Fax: 41-22-884-1556
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.00
• High Stock Price Target: $30.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +294.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,760,000.00
• Net Margins: 850.30%
• Pretax Margin: -1,106.55%
• Return on Equity: -112.43%
• Return on Assets: -77.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.59
• Quick Ratio: 4.59

Sales & Book Value

• Annual Sales: $556,045.00
• Price / Sales: 14.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.20 per share
• Price / Book: 6.34

Miscellaneous

• Outstanding Shares: 1,060,000
• Free Float: 901,000
• Market Cap: $8.07 million
• Optionable: Not Optionable
• Beta: 1.76